Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Iovance Biotherapeutics (IOVA) EBT Margin (2023 - 2025)

Iovance Biotherapeutics has reported EBT Margin over the past 4 years, most recently at 82.65% for Q4 2025.

  • Quarterly results put EBT Margin at 82.65% for Q4 2025, up 2183.0% from a year ago — trailing twelve months through Dec 2025 was 149.16% (up 7940.0% YoY), and the annual figure for FY2025 was 149.16%, up 7940.0%.
  • EBT Margin for Q4 2025 was 82.65% at Iovance Biotherapeutics, up from 138.85% in the prior quarter.
  • Over the last five years, EBT Margin for IOVA hit a ceiling of 82.65% in Q4 2025 and a floor of 44960.08% in Q2 2023.
  • Median EBT Margin over the past 3 years was 239.24% (2025), compared with a mean of 10109.0%.
  • Biggest five-year swings in EBT Margin: skyrocketed 4464324bps in 2024 and later skyrocketed 642bps in 2025.
  • Iovance Biotherapeutics' EBT Margin stood at 24509.96% in 2023, then surged by 100bps to 104.49% in 2024, then increased by 21bps to 82.65% in 2025.
  • The last three reported values for EBT Margin were 82.65% (Q4 2025), 138.85% (Q3 2025), and 182.93% (Q2 2025) per Business Quant data.